LettersDrs. Craig Ritchie and David Ames Reply
Reference (1)
- et al.
Metal attenuation with iodohydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer's disease
Arch Neurol
(2003)
Cited by (5)
Imaging treatment effects in Alzheimer's disease
2007, Magnetic Resonance ImagingCitation Excerpt :This factor represents a major confound when assessing effects which are very small in size. The use of conventional drug trial designs in pharmacological research in AD has been criticised [56] and may be one of the factors hampering speedy drug development (and the assessment of their effects) in AD. A pattern of increased glucose metabolism confined to the left caudate was found in 19 mild to moderate AD patients after 8 weeks of treatment with galantamine [57].
Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine
2007, Dementia and Geriatric Cognitive DisordersComparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors
2007, Acta Biomedica de l'Ateneo ParmenseEffects of cholinergic drugs and cognitive training on dementia: 2-Year follow-up
2006, Dementia and Geriatric Cognitive Disorders
Craig Ritchie has received research support, honoraria, and/or financial assistance with conference attendance from Prana Biotechnology, Janssen Cilag, Pfizer-Eisai, Eli-Lilly, Shire Pharmaceuticals, Roche, and Glaxo Smith Kline.
David Ames has received research support, honoraria, and/or financial assistance with conference attendance from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Hoechst Marion Roussel, Janssen Cilag, Lundbeck, Novartis, Parke-Davis, Pfizer, Protodigm, Quintiles, Roche, Sandoz, Sanofi Synthelabo, and SmithKlineBeecham.